Searched for: school:LISOM
Management of high-grade ovarian adenocarcinoma in an intraperitoneal pelvic renal transplant recipient
Erfani, Hadi; Demirel, Esra; Nezhat, Farr
BACKGROUND/UNASSIGNED:The increasing number of organ transplant recipients has led to a rise in cancer diagnoses in this population. Kidney transplant recipients, in particular, have a two-to-four-fold higher risk of developing cancer due to immunosuppressive therapy. The management of gynecologic cancers in this subset of patients presents unique challenges due to anatomical considerations, immunosuppression, and the nephrotoxicity of oncologic treatments.Case Presentation.A 44-year-old woman with a history of polycystic kidney disease underwent a bilateral nephrectomy followed by a living-related intraperitoneal renal transplant. She presented with pelvic pain and was found to have high-grade ovarian adenocarcinoma, possibly arising from endometriosis. Surgical staging included total laparoscopic hysterectomy, bilateral salpingo-oophorectomy, omentectomy, and right pelvic lymph node dissection. The patient underwent six cycles of carboplatin and paclitaxel chemotherapy while maintaining stable renal function with close monitoring of immunosuppressive drug levels. Surveillance imaging detected recurrence in the right pelvic lymph nodes, leading to secondary tumor debulking and whole pelvic radiation therapy. Despite a slight increase in creatinine, kidney function remained stable, and the patient has remained disease-free on subsequent follow-ups. CONCLUSION/UNASSIGNED:The management of ovarian cancer in kidney transplant recipients requires a multidisciplinary approach to balance oncologic control with graft preservation. Close monitoring of renal function, careful surgical planning, and tailored chemotherapy and radiation strategies are critical. More research is needed to establish standardized guidelines for managing gynecologic malignancies in transplant patients.
PMCID:12134479
PMID: 40469881
ISSN: 2352-5789
CID: 5862642
Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS study
Usmani, Saad Z; Facon, Thierry; Hungria, Vania; Bahlis, Nizar J; Venner, Christopher P; Braunstein, Marc; Pour, Ludek; MartÃ, Josep M; Basu, Supratik; Cohen, Yael C; Matsumoto, Morio; Suzuki, Kenshi; Hulin, Cyrille; Grosicki, Sebastian; Legiec, Wojciech; Beksac, Meral; Maiolino, Angelo; Takamatsu, Hiroyuki; Perrot, Aurore; Turgut, Mehmet; Ahmadi, Tahamtan; Liu, Weiping; Wang, Jianping; Chastain, Katherine; Vermeulen, Jessica; Krevvata, Maria; Lopez-Masi, Lorena; Carey, Jodi; Rowe, Melissa; Carson, Robin; Zweegman, Sonja
Frontline daratumumab-based triplet and quadruplet standard-of-care regimens have demonstrated improved survival outcomes in newly diagnosed multiple myeloma (NDMM). For patients with transplant-ineligible NDMM, triplet therapy with either daratumumab plus lenalidomide and dexamethasone (D-Rd) or bortezomib, lenalidomide and dexamethasone (VRd) is the current standard of care. This phase 3 trial evaluated subcutaneous daratumumab plus VRd (D-VRd) in patients with transplant-ineligible NDMM or for whom transplant was not planned as the initial therapy (transplant deferred). Some 395 patients with transplant-ineligible or transplant-deferred NDMM were randomly assigned to eight cycles of D-VRd or VRd followed by D-Rd or Rd until progression. The primary endpoint was overall minimal residual disease (MRD)-negativity rate at 10-
PMID: 39910273
ISSN: 1546-170x
CID: 5784142
The utility of the aortogram: contrast staining from an undiagnosed chronic aortic dissection [Case Report]
Tejada Frisancho, Flavia; Wallace, Ryan; Medranda, Giorgio; Case, Brian
PMCID:12032395
PMID: 40290173
ISSN: 2514-2119
CID: 5832992
Utility of Parathyroid Autofluorescence in Differentiating Parathyroid Pathology
Hsu, Shawn Y; Kuo, Eric J; McManus, Catherine; Liou, Rachel; Lee, James A; Kuo, Jennifer H
BACKGROUND:Near-infrared autofluorescence (NIRAF) spectroscopy is an emerging adjunct for intraoperative parathyroid identification. However, its ability to differentiate between normocellular, hyperplastic, or adenomatous parathyroids remains unexplored. We hypothesize that parathyroid adenomas have lower NIRAF ratios than normocellular parathyroids since the likely fluorophore is the calcium-sensing receptor (CaSR), which is downregulated in adenomas. METHODS:In vivo NIRAF ratios for each identified parathyroid gland were recorded for patients undergoing thyroidectomy or parathyroidectomy from 08/2023 to 12/2023 at a single institution. Parathyroids were categorized as normocellular by visual inspection and hyperplastic or adenomatous by final histology. RESULTS:Of the 44 patients included (66% underwent parathyroidectomy and 34% underwent thyroidectomy), 137 parathyroids were identified intraoperatively with 66 resected and analyzed histologically. A total of 71 (52%) parathyroids were normocellular, 45 (33%) were hyperplastic, and 21 (15%) were adenomatous. Among the resected parathyroids, there was moderate agreement (81%) between visual categorization and final histology for hyperplasia versus adenoma (κ = 0.6). Parathyroid adenomas had lower median NIRAF ratios than normocellular parathyroids (p = 0.0005). Median NIRAF ratios were not significantly different between normocellular and hyperplastic parathyroids (p = 0.35) nor between hyperplastic parathyroids and adenomas (p = 0.04). The performance of NIRAF spectroscopy in differentiating parathyroid pathology is poor based on receiver operator characteristics analysis. CONCLUSION:Parathyroid adenomas have lower NIRAF ratios than normocellular parathyroids. However, the performance of using NIRAF ratios to differentiate between parathyroid pathology is poor. Therefore, the differences in NIRAF ratios are unlikely to be sufficient at point-of-care use to distinguish between various parathyroid pathologies. As NIRAF ratios are highest in normocellular parathyroid glands, NIRAF appears to be most useful in detecting normal parathyroid glands.
PMID: 40044447
ISSN: 1432-2323
CID: 5865602
Deep learning model for detecting high-grade dysplasia in colorectal adenomas
Steimetz, Eric; Simsek, Zeliha Celen; Saha, Asmita; Xia, Rong; Gupta, Raavi
OBJECTIVE/UNASSIGNED:Early detection and removal of suspicious polyps during routine colonoscopies play an important role in reducing the risk of colorectal cancer. Patient management and follow-up are determined by the type of polyps removed and the degree of dysplasia present on histological evaluation. Whereas discerning between a benign polyp and a dysplastic one is a trivial task, distinguishing between tubular adenomas with low-grade dysplasia (LGD) and high-grade dysplasia (HGD) is a challenging task. In this study, we trained a deep learning model to distinguish between colorectal adenomas with LGD and HGD. DESIGN/UNASSIGNED:We retrieved 259 slides of adenomatous polyps taken between January 2011 and October 2024. Slides with HGD were reviewed by a subspecialty-trained GI pathologist. After excluding discordant and duplicate cases, 200 slides remained: 71 (35.5%) with HGD and 129 (64.5%) with LGD. The slides were divided into training (160 slides, 80%) and test (40 slides, 20%) sets. After patch generation and stain normalization, a ResNet34 model (pre-trained on ImageNet) was trained using 5-fold cross-validation. Slide classification was determined by aggregating patch-level predictions. RESULTS/UNASSIGNED:The model's slide-level prediction accuracy was 95.0%, correctly classifying all but 2 out of 40 slides. The model achieved an area under the receiver operating characteristic curve score of 0.981 and an F1 score of 0.923. CONCLUSIONS/UNASSIGNED:This study demonstrates that deep learning models can accurately distinguish between colonic adenomas with LGD and HGD. Training on a larger dataset could increase the accuracy and generalizability of the model and should be a focus of further studies.
PMCID:12130978
PMID: 40463412
ISSN: 2229-5089
CID: 5862342
Enhanced Total Weight Loss 2 Years Post-Roux-en-Y Gastric Bypass with Longer Biliopancreatic Limb
Yoshida, Miya C; Luong, Diana; Tan, Sally; Pan, Jennifer; Luu, Jonathan; Pyke, Owen; Kella, Venkata; Brathwaite, Collin E M; Levine, Jun
BACKGROUND:Despite widespread use of Roux-en-Y gastric bypass (RYGB), there are no standardized limb lengths in the United States. METHODS:A multi-center retrospective cohort study was conducted from 2020 to 2023. Eligible patients who had undergone RYGB were divided into subgroups based on BP limb lengths: short (50-75 cm), intermediate (80-125 cm), and long (150-175 cm). Primary outcomes were total weight loss (TWL) and % TWL at 1 and 2 years. Secondary outcomes were post-operative BMI and % BMI change at 1 and 2 years, micronutrient deficiencies, hypothyroidism, acute kidney injury (AKI) requiring treatment, and remission in associated medical problems. Subgroups were compared using multivariate analysis. RESULTS:Two hundred twenty-eight patients received a long BP limb, 194 patients received an intermediate BP limb, while 152 patients received a short BP limb. Primary outcomes TWL and % TWL were significantly different between the groups at 1 year: TWL and % TWL were greater in patients with long BP limbs. The difference between the long and short BP limb groups increased at the 2-year mark. Patients who had long BP limbs had higher rates of DM remission (12.3% vs 11.9% 6.6%), HTN (8.8% vs 5.7% vs 7.9%), GERD symptoms (14.5% vs 9.8% vs 5.3%), and OSA (8.8% vs 7.7% vs 5.3%). Vitamin A deficiency rates were higher in the long BP limb group. CONCLUSIONS:The results suggest that longer BP limb lengths are conducive to TWL and overall treatment of obesity-related problems without severe rates of complications. Additional longer longitudinal studies are needed to assess the impact of long BP limbs on nutrition and weight loss in the long term.
PMID: 40100614
ISSN: 1708-0428
CID: 5813272
Stercoral Colitis: Review of Imaging Features and Complications
Karkala, Nikitha; Mathai, Bertin; Hines, John J; Byun, Sarah; Katz, Douglas S
Stercoral colitis is an inflammatory reaction secondary to fecal impaction and almost always occurs in the setting of chronic constipation. Luminal distention caused by dense and dehydrated stool compresses the vascular supply of the distal colon, resulting in bowel ischemia and ulceration. Stercoral colitis primarily affects elderly patients, but it can be seen in any patient with decreased bowel motility, with risk factors including neurodegenerative disorders, chronic medical diseases, malignancy, immobility, and the use of narcotic or anticholinergic medications. Patients most often present with abdominal pain and tenderness. However, the presentation is often nonspecific and can include nongastrointestinal symptoms. Due to the common presence of comorbidities, a thorough history and physical examination findings may be difficult to obtain. Imaging, especially CT, plays a vital role in the diagnosis of stercoral colitis, demonstrating hallmark features such as fecal impaction and a large colorectal stool burden. Mural thickening (>3 mm) and other CT signs of inflammation aid in diagnosis, although findings including perirectal fat stranding can be nonspecific. Signs of perforation, including mural discontinuity, extraluminal air, and extraluminal stool collections, can also be identified. Other potential complications include obstruction, bleeding, fistulas, and urinary tract involvement secondary to mass effect. The overlap of findings between stercoral colitis and other colonic diseases, particularly diverticulitis and malignancy, can sometimes make diagnosis challenging. Identification of fecal impaction and associated inflammatory changes helps in distinguishing stercoral colitis from other pathologic conditions. Prompt diagnosis of stercoral colitis and its complications allows appropriate management, which can range from preventive measures to emergent surgical treatment. ©RSNA, 2025 Supplemental material is available for this article.
PMID: 40146627
ISSN: 1527-1323
CID: 5816792
Digital PCR Assay Utilizing In-Droplet Methylation-Sensitive Digestion for Estimation of Fetal cfDNA From Plasma
Dannebaum, Richard; Mikhaylichenko, Olga; Siegel, David; Li, Chenyu; Hall, Eric; Margeridon, Severine; Herrera, Monica; Loomis, Kristin; Riel, Thea; Ramesh, Madhumita; Gencoglu, Maria; Hendel, Nathan; Henriquez, Anthony; Dzvova, Nyari; Abayan, Raymond-John; Lin, Xinhua; Chavez, Martin; Hanna, Nazeeh
OBJECTIVE:Recent guidelines suggest that non-invasive prenatal screening (NIPS) should be offered to all patients with singleton and twin pregnancies. Accurate determination of fetal fraction in cell-free DNA (cfDNA) is vital for reliable NIPS outcomes. We propose a methylation-based approach using droplet digital PCR (ddPCR) and methylation-sensitive restriction enzyme (MSRE) digestion for fetal fraction quantification as an affordable and fast solution. METHOD/METHODS:Following biomarker discovery using early pregnancy placental genomic DNA (gDNA) and cfDNA from non-pregnant female individuals, we designed assays targeting MSRE-compatible regions based on contrasting methylation patterns between maternal and fetal cfDNA. We established a proof-of-concept ddPCR workflow on the Bio-Rad Droplet Digital PCR QX600 instrument. RESULTS:Testing the fetal fraction assay multiplex on 137 prospective clinical samples demonstrated high concordance with NGS results for both female and male pregnancies as well as with chromosome Y-based calculations for samples with a male fetus. Reproducibility analysis indicated lower variability compared to previously reported NGS performance. CONCLUSION/CONCLUSIONS:This study showcases the potential of this novel, 6-color, high-multiplex methylation ddPCR panel for accurate measurement of fetal fraction in cfDNA samples. It presents opportunities to integrate such methodology as a standalone measurement to assess the quality of samples undergoing NIPS.
PMID: 40090860
ISSN: 1097-0223
CID: 5812942
North American Expert Consensus on the Post-procedural Care of Patients After Per-oral Endoscopic Myotomy Using a Delphi Process
Yang, Dennis; Mohammed, Abdul; Yadlapati, Rena; Wang, Andrew Y; Jeyalingam, Thurarshen; Draganov, Peter V; Gonzaga, Ernesto Robalino; Hasan, Muhammad K; Schlachterman, Alexander; Xu, Ming-Ming; Saeed, Ahmed; Aadam, Aziz; Sharaiha, Reem Z; Law, Ryan; Wong Kee Song, Louis M; Saumoy, Monica; Pandolfino, John E; Nishimura, Makoto; Kahaleh, Michel; Hwang, Joo Ha; Bechara, Robert; Konda, Vani Ja; DeWitt, John M; Kedia, Prashant; Kumta, Nikhil A; Inayat, Irteza; Stavropoulos, Stavros N; Kumbhari, Vivek; Siddiqui, Uzma D; Jawaid, Salmaan; Andrawes, Sherif; Khashab, Mouen; Triggs, Joseph R; Sharma, Neil; Othman, Mohamed; Sethi, Amrita; Baumann, Alexandra J; Priraka, Cyrus; Dunst, Christy M; Wagh, Mihir S; Al-Haddad, Mohammad; Gyawali, C Prakash; Kantsevoy, Sergey; Elmunzer, B Joseph
BACKGROUND & AIMS/OBJECTIVE:There is significant variability in the immediate post-operative and long-term management of patients undergoing per-oral endoscopic myotomy (POEM), largely stemming from the lack of high-quality evidence. We aimed to establish a consensus on several important questions on the after care of post-POEM patients through a modified Delphi process. METHODS:A steering committee developed an initial questionnaire consisting of 5 domains (33 statements): post-POEM admission/discharge, indication for immediate post-POEM esophagram, peri-procedural medications and diet resumption, clinic follow-up recommendations, and post-POEM reflux surveillance and management. A total of 34 experts participated in the 2 rounds of the Delphi process, with quantitative and qualitative data analyzed for each round to achieve consensus. RESULTS:A total of 23 statements achieved a high degree of consensus. Overall, the expert panel agreed on the following: (1) same-day discharge after POEM can be considered in select patients; (2) a single dose of prophylactic antibiotics may be as effective as a short course; (3) a modified diet can be advanced as tolerated; and (4) all patients should be followed in clinic and undergo objective testing for surveillance and management of reflux. Consensus could not be achieved on the indication of post-POEM esophagram to evaluate for leak. CONCLUSIONS:The results of this Delphi process established expert agreement on several important issues and provides practical guidance on key aspects in the care of patients following POEM.
PMID: 39214390
ISSN: 1542-7714
CID: 5821512
Adverse Pregnancy Outcomes in Sjogren's Disease Compared to Controls: An Interdisciplinary Approach with Maternal-Fetal Medicine
Tesoriero, Lauren; Kidd, Jennifer; Piccione, Julie; Izmirly, Peter; Akerman, Meredith; Carsons, Steven; Rekawek, Patricia; Nusbaum, Julie
OBJECTIVES/UNASSIGNED:Outside of the association of SS-A antibody with congenital heart block, little is known about adverse maternal and neonatal outcomes, in patients with Sjogren's disease (SjD). Our study involved collaboration with maternal-fetal medicine (MFM). METHODS/UNASSIGNED:-test and Fisher's exact test. RESULTS/UNASSIGNED:48 patients were included: 12 SjD patients and 36 controls. APO was significantly increased in SjD with one preterm birth, one fetal growth restriction, and one limb anomaly; non-SjD had one cardiac anomaly. There were no cases of CHB. SjD patients were more likely to be delivered by cesarean delivery. CONCLUSION/UNASSIGNED:There was an increased risk of APO in SjD patients compared with controls. No significant difference in neonatal outcomes was found. We speculate that placental pathology may play a role in pathophysiology and future studies should be performed. KEY POINTS/UNASSIGNED:There was an increased risk of APO in SjD patients compared with controls.No significant difference in neonatal outcomes was found.We speculate that placental pathology may play a role in pathophysiology, prompting future studies.
PMCID:12020534
PMID: 40291586
ISSN: 2157-6998
CID: 5833052